Furanopyrimidine compounds as potassium ion channel inhibitors

Details Furanopyrimidine compounds as potassium ion channel inhibitors Furanopyrimidine compounds as potassium ion channel inhibitors

2005-06-10

2008-11-25

Coleman, Brenda L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S278000

Reexamination Certificate

active

07456187

ABSTRACT:
A compound of formula (I)whereinR1is aryl, heteroaryl, cycloalkyl or alkyl;R2is H, alkyl, nitro, —CO2R7, CONR4R5or halo;R3is H, NR4R5, NC(O)R8, halo, trifluoromethyl, alkyl, nitrile or alkoxy;R4and R5may be the same or different, and may be H, alkyl, aryl, heteroaryl or cycloalkyl; or R4and R5may together form a saturated, unsaturated or partially saturated 4 to 7 member ring, wherein said ring may optionally comprise one or more further heteroatoms selected from N, O or S;X is O, S or NR6;R6is H or alkyl;R7is hydrogen, methyl or ethyl;R8is methyl or ethyl;L is (CH2)n, where n is 1, 2 or 3; andY is aryl, a heterocyclic group, alkyl, alkenyl or cycloalkyl;together with pharmaceutically acceptable salts thereof. The use of these compounds as potassium channel inhibitors is also described.

REFERENCES:
patent: 4199584 (1980-04-01), Cox et al.
patent: 5137879 (1992-08-01), Edie et al.
patent: 6531495 (2003-03-01), Brendel et al.
patent: 2002/0161011 (2002-10-01), Beaudoin et al.
patent: 2003/0027829 (2003-02-01), Reed et al.
patent: 2005/0026935 (2005-02-01), Ford et al.
patent: 2006/0183768 (2006-08-01), Ford et al.
patent: 2007/0161672 (2007-07-01), Ford et al.
patent: 521790 (1979-11-01), None
patent: 226 893 (1985-09-01), None
patent: 101 04 802 (2002-08-01), None
patent: 1 570 494 (1980-07-01), None
patent: 48-81892 (1973-11-01), None
patent: 48-81893 (1973-11-01), None
patent: 2 116 309 (1998-07-01), None
patent: WO 98/04521 (1998-02-01), None
patent: WO 98/04542 (1998-02-01), None
patent: WO 98/18475 (1998-05-01), None
patent: WO 98/18476 (1998-05-01), None
patent: WOX 99/37607 (1999-07-01), None
patent: WO 99/62891 (1999-12-01), None
patent: WO 00/12492 (2000-03-01), None
patent: WO 00/25774 (2000-05-01), None
patent: WO 01/00573 (2001-01-01), None
patent: WO 01/21609 (2001-03-01), None
patent: WO 01/21610 (2001-03-01), None
patent: WO 01/25189 (2001-04-01), None
patent: WO 01/25224 (2001-04-01), None
patent: WO 01/40231 (2001-06-01), None
patent: WO 01/46155 (2001-06-01), None
patent: WO 02/24655 (2002-03-01), None
patent: WO 01/27107 (2002-04-01), None
patent: WO 02/36556 (2002-05-01), None
patent: WO 02/44137 (2002-06-01), None
patent: WO 02/46162 (2002-06-01), None
patent: WO 02/48131 (2002-06-01), None
patent: WO 02/064581 (2002-08-01), None
patent: WO 02/087568 (2002-11-01), None
patent: WO 02/088073 (2002-11-01), None
patent: WO 02/100825 (2002-12-01), None
patent: WO 03/000675 (2003-01-01), None
patent: WO 03/063797 (2003-08-01), None
Hackler et. al. (Special Publication—Royal Society of Chemistry., 1994, 147, 70-84). CAS print out 44/74.
Belenkii et. al. (Khimiya Geterotsiklicheskikh, 1993, 1, 124-129) CAS printount 46/74.
Amos, G.J., et al., “Differences between outward currents of human atrial and subepicardial ventricular myocytes,”J. Physiol. 491:31-50, Cambridge Univ. Press. (1996).
Armstrong, C.M. and Hille, B., “Voltage-Gated Ion Channels and Electrical Excitability,”Neuron 20:371-380, Cell Press (1998).
Bachmann, A., et al., “Characterization of a novel Kv1.5 channel blocker inXenopusoocytes, CHO cells, human and rat cardiomyocytes,”Naunyn-Schmiedeberg's Arch. Pharmacol. 364:472-478, Springer-Verlag (2001).
Belen'kii, L.I., et al., “Synthesis of Heterocyclic Compounds from the Products of Addition of Polyhaloalkanes to Unsaturated Systems. 4. Synthesis of Substituted Furo[2,3-D]Pyrimidines,”Chemistry of Heterocyclic Compounds29:109-114, Plenum Publishing Corporation (1993).
Brendel, J. and Peukert, S., “Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias,”Expert Opin. Ther. Patents 12:1589-1598, Ashley Publications Ltd. (2002).
Campaigne, E., “Thiophenes and their Benzo Derivatives: (iii) Synthesis and Applications,” inComprehensive Heterocyclic Chemistry: The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds 4, Bird, C.W., et al., eds., Pergamon Press, New York, NY, pp. 863-934 (1984).
Colatsky, T.J., et al., “Channel Specificity in Antiarrhythmic Drug Action: Mechanism of Potassium Channel Block and Its Role in Suppressing and Aggravating Cardiac Arrhythmias,”Circulation 82:2235-2242, American Heart Association (1990).
Courtemanche, M.,, et al., “Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model,”Cardiovasc. Res. 42:477-489, Elsevier Science B. V. (1999).
Fedida, D., et al., “Identity of a Novel Delayed Rectifier Current From Human Heart With a Cloned K+Channel Current,”Circ. Res. 73:210-216, Lippincott Williams & Wilkins (1993).
Feng, J., et al., “Antisense Oligodeoxynucleotides Directed Against Kv1.5 mRNA Specifically Inhibit Ultrarapid Delayed Rectifier K+Current in Cultured Adult Human Atrial Myocytes,”Cir. Res. 80:572-579, American Heart Association, Inc. (1997).
Feng, J., et al., “Effects of Class III Antiarrhythmic Drugs on Transient Outward and Ultra-rapid Delayed Rectifier Currents in Human Atrial Myocytes,”J. Pharmacol. Exp. Ther. 281:384-392, American Society for Pharmacology and Experimental Therapeutics (1997).
Ford, J. W., et al., “Potassium Channels: Gene Family, Therapeutic Relevance, High-Throughput Screening Technologies and Drug Discovery,” inProgress in Drug Research, vol. 58, Jucker, E., ed., Birkhäuser Verlag, Boston, MA, pp. 133-168 (2002).
Godreau, D., et al., “Mechanisms of Action of Antiarrythmic Agent Bertosamil on hKv1.5 Channels and Outward Potassium Current in Human Atrial Myocytes,”J. Pharmacol. Exp. Ther. 300:612-620, American Society for Pharmacology and Experimental Therapeutics (2002).
Gutman, G.A., et al., “International Union of Pharmacology. XLI. Compendium of Voltage-Gated Ion Channels: Potassium Channels,”Pharmacol. Rev. 55:583-586, American Society for Pharmacology and Experimental Therapeutics (Dec. 2003).
Herbert, S.C., “General Principles of the Structure of Ion Channels,”Am. J. Med. 104:87-98, Excerpta Medica, Inc. (1998).
Hosni, H.M., et al., “Thienopyrimidines II: Synthesis of Newer Thieno[2,3-d]-Pyrimidines and Their Quaternized Derivatives with Molluscicidal Activity,”Acta Pol. Pharm.—Drug Res. 56:49-56, Polish Pharmaceutical Society (1999).
Hozien, Z.A., et al., “Synthesis and Application of Some New Thienopyrimidine Dervatives as Antimicrobial Agents,”Synthetic Communications 26:3733-3755, Marcel Dekker, Inc. (1996).
Ismail, K.A., et al., “Synthesis and Antimicrobial Activity of Some Tetramethylenethieno[2,3-d]pyrimidine derivatives,”Il Farmaco 50:611-616, Elsevier (1995).
Jordis, U., et al., “7,9-Dideaza-9-Thiaadenines (4-Aminothieno/2,3-d/pyrimidines) as Potential Anticytokinines,”Vestn. Slov. Kem. Drus. 33:217-238, Drustvo (1986).
Katada, J., et al., “Cytotoxic effects of NSL-1406, a new thienopyrimidine derivative, on leukocytes and osteoclasts,”Bioorg. Med. Chem. Lett. 9:797-802, Elsevier Science Ltd. (1999).
Knobloch, K., et al., “Electrophysiological and antiarrhythmic effects of the novelIKurchannel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with theIKrblockers dofetilide, azimilide, d,l-sotalol and ibutilide,”Naunyn-Schmiedeberg's Arch. Pharmacol. 366:482-487, Springer-Verlag (2002).
Konno, S., et al., “Synthesis of Thienopyrimidine Derivatives and Their Antifungal Activities,”Yakugaku Zasshi 109:464-473, Pharmaceutical Society of Japan (1989).
Li, G.-R., et al., “Evidence for Two Components of Delayed Rectifier K+Current in Human Ventricular Myocytes,”Circ. Res. 78:689-696, American Heart Association, Inc. (1996).
Malayev, A.A., et al., “Mechanism of Clofilium Block of the Human Kv1.5 Delayed Rectifier Potassium Channel,”Mol. Pharmacol. 47:198-205, American Society for Pharmacology and Experimental Therapeutics (1995).
Marbán, E., “Cardiac channelopathies,”Nature 415:213-218,

Affiliated with

Also associated with

Rating

Furanopyrimidine compounds as potassium ion channel inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Furanopyrimidine compounds as potassium ion channel inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Furanopyrimidine compounds as potassium ion channel inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4048607